Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Biosimilar Advisory Committee Policy Evolves

Executive Summary

If first-in-class biosimilar doesn't raise new scientific issues, it may not need advisory committee meeting, FDA's Christl says in interview with the Pink Sheet, suggesting a case-by-case approach going forward.

Advertisement

Related Content

US FDA's Biosimilars Chief Leah Christl Plans Departure
Biosimilars: US FDA Expecting More Applications, Fewer Applicants
Mylan's Fulphila Approval: Lack Of US FDA AdComm May Be A Positive For Biosimilar Industry
Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky
US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards
Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start
Pending Biosimilars
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel